Loading...
XNAS
NDRA
Market cap3mUSD
Jul 09, Last price  
5.49USD
1D
15.34%
1Q
11.13%
IPO
-100.00%
Name

ENDRA Life Sciences Inc

Chart & Performance

D1W1MN
XNAS:NDRA chart
P/E
P/S
EPS
Div Yield, %
Shrs. gr., 5y
-3.89%
Rev. gr., 5y
-70.98%
Revenues
0k
559,3551,410,065515,582351,6226,1740000000
Net income
-7m
L-38.93%
-2,180,878-2,279,204-2,775,368-5,376,962-9,796,261-13,305,964-11,725,501-11,231,250-13,179,092-10,060,250-11,507,947-7,027,410
CFO
-5m
L-29.97%
-1,397,229-842,727-1,315,623-3,300,914-7,702,481-8,588,851-10,770,595-11,122,384-12,769,371-9,548,775-7,400,547-5,182,558

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
IPO date
Jun 28, 2017
Employees
21
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT